{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a palmitate
to a specific field?
Class (Stereo):
CHEMICAL (MIXED)
Iosimenol, is a synthetic non-ionic dimeric contrast medium with lower molecular weight patented by Schering A.-G. In clinical trials Iosimenol was not metabolized, had a distribution volume corresponding to the extracellular space, and was rapidly excreted through the kidneys by glomerular filtration. The area under the plasma concentration curve and the peak plasma concentration was proportional to dose, while clearance was independent of dose. Iosimenol upon intravenous as well as upon intra-arterial injection exhibits a safety profile and shows an efficacy similar to that of iodixanol.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Ciprostene is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-induced platelet aggregation. Ciprostene was evaluated in clinical trials in patients with peripheral vascular disease. It was found to reduce restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty.
Status:
Investigational
Source:
INN:ciclazindol [INN]
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Ciclazindol is an indole derivative and monoamine uptake inhibitor patented by pharmaceutical company John Wyeth and Brother Ltd. as an antidepressant. Besides that, Ciclazindol is effective anorectic agent, inducing weight loss in rats and man. Ciclazindol was shown to inhibit ATP-sensitive K+ (K(ATP)) channel currents and stimulate insulin secretion from CRI-G1 insulin-secreting cells. The inhibition of KATP channel currents by ciclazindol is unaffected by the removal of intracellular Mg2+ ions and after trypsinization of the cytoplasmic surface of excised patches, treatments known to abolish sulphonylurea sensitivity.
Class (Stereo):
CHEMICAL (RACEMIC)
Miroprofen, an imidazopyridine derivative, possesses anti-inflammatory properties. It was shown that this compound could be effective in suppressing pain responses and acute inflammation accompanied by increased vascular permeability. Analgesic effect of this compound was studied in post-extraction pain. However, information about the current study of this agent is not available.
Class (Stereo):
CHEMICAL (MIXED)
Imoxiterol (also known as RP 58802B) is benzimidazole derivatives patented by pharmaceutical company Laboratoire Roger Bellon S. A as a long-acting β-adrenergic agonist. In preclinical models, nebulized Imoxiterol produced a rapid onset and long-lasting inhibition of histamine-induced bronchospasm in the anaesthetized guinea-pig. Given orally, Imoxiterol produced a greater than three-fold shift to the right of the dose-response curve and depressed the maximum response to histamine. Imoxiterol prevented the development of bronchial hyperreactivity. Although PAF-induced bronchial hyperreactivity was not accompanied by an increase in the number of pulmonary eosinophils, Imoxiterol reduced the numbers of eosinophils recovered by lavage. Imoxiterol significantly inhibited PAF-induced microvascular leakage into guinea-pigs lung.
Status:
Investigational
Source:
NCT01969357: Phase 2 Interventional Completed Type 2 Diabetes
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
SP-2086 H3PO4 (Retagliptin Phosphate), tetrahydro-imidazo[1,5-a] pyrazine
derivative, is a competitive DPP-4 inhibitor innovated in China under development by Jiangsu Hengrui Medicine for the treatment of Type 2 diabetes. In completed phase II trials, retagliptin monotherapy or in combination with metformin significantly decreased the HbA1c level in type 2 diabetic patients. Two phase III trials for retagliptin monotherapy aCnd in combination with metformin, respectively, were ongoing in China. Jiangsu Hengrui Medicine withdrew its application from the Chinese
FDA in April 2016 but is expected to refile the application.
Status:
Investigational
Source:
NCT00891241: Phase 1 Interventional Completed Heart Failure
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01107236: Phase 2 Interventional Completed Healthy
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01668147: Phase 1/Phase 2 Interventional Completed Drug Effects
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:diacetamate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Diacetamate (Acetaminophen Acetate, Acetaminophen Impurity, diacetyl-p-aminophenol) is a acetaminophen synthetic impurity. Acetaminophen-aspirin
mixtures have lower stability due to acetylation of the former
by the latter, producing diacetyl-p-aminophenol.
